ONGOING SYMPTOMATIC COVID-19 – PHARMACOTHERAPY POSSIBILITIES
Authors:   Main Military Clinical Hospital named after Academician N.N. Burdenko, ZAITSEV ANDREY A. , TERNOVSKAYA NINA A. ,   Main Military Clinical Hospital named after Academician N.N. Burdenko, CHELAN EKATERINA A. ,   Main Military Clinical Hospital named after Academician N.N. Burdenko, KULAGINA IRINA TS. ,   Main Military Clinical Hospital named after Academician N.N. Burdenko, SIDOROV YURI A. ,   Main Military Clinical Hospital named after Academician N.N. Burdenko, LIKHODIY VYACHESLAV I. ,   Main Military Clinical Hospital named after Academician N.N. Burdenko
Published: July 2022

Introduction. The medical community continues to search for modern methods of treating the ongoing symptomatic COVID-19 and post-COVID syndrome. Among all symptoms of ongoing symptomatic COVID-19, respiratory disorders are the most challenging and leading not only to impaired quality of life, but also to patient's disability. Thus, it seems relevant to study various options for the treatment of ongoing symptomatic COVID-19, including drugs with adaptogenic effects. Aim. The aim of the study was to seek the effects of the drug Trecresan on the recovery of patients who had COVID-19 (reduction of the severity of asthenia, restoration of lung function and other indicators) in comparison with standard (real practice) therapy of patients who incurred a new coronavirus infection COVID-19. To evaluate and conduct a comparative analysis of the safety of the treatment regimens used for "ongoing symptomatic COVID-19" with patients who have moderate and severe case of a new coronavirus infection. Material and methods. The study included 103 patients with ongoing symptomatic COVID-19 who were hospitalized in a pulmonology department. The first group included 53 patients who were treated with the drug Trecresan, the 2nd group included 50 patients. During the examination of patients, the following was performed: A comprehensive study of lung function, including the designation of the diffusion capacity of the lungs - DLCO, the level of SpO2 (saturation), a 6-minute walking test, an assessment asthenia severity on the MFI-20 (Multidimensional Fatigue Inventory) scale. The clinical efficiency of complex therapy was analyzed after 8-10 days of treatment. The endpoints necessary for subsequent analysis were the timing of COVID-19 symptoms resolution (severity of asthenia, performance, etc.) and adverse events developed during treatment. Results and discussion. The inclusion of the drug Trekrezan in the treatment of patients with ongoing symptomatic COVID-19 led to an improvement in overall well-being. There was a significant decrease in the severity of asthenia on the MFI-20 scale, a statistically significant decrease in the degree of shortness of breath and improvement in the patient’s quality of life were revealed, a decrease in the inpatient period was noted. Conclusion. It has been established that medium-term therapy using the adaptogen Trekrezan with patients with ongoing symptomatic COVID-19 and post-COVID syndrome reduces the severity of symptoms of the disease, increases exercise tolerance, reduces the severity of asthenia on the MFI-20 scale, reduces the inpatient period.